Search

Your search keyword '"Rosenblat, Joshua D"' showing total 872 results
Start Over Author "Rosenblat, Joshua D"
872 results on '"Rosenblat, Joshua D"'

102. Association of SARS-CoV-2 infection with neurological impairments in pediatric population: A systematic review

Author

Kwan, Angela T.H., primary, Al-Kassimi, Khaled, additional, Portnoff, Jacob S., additional, Singh, Gurkaran, additional, Hanafimosalman, Mehrshad, additional, Tesla, Marija, additional, Gharibi, Nima, additional, Ni, Tiffany, additional, Guo, Ziji, additional, Sonfack, Davaine J.N., additional, Martyniuk, Julia, additional, Arfaie, Saman, additional, Mashayekhi, Mohammad Sadegh, additional, Mofatteh, Mohammad, additional, Jeremian, Richie, additional, Ho, Kevin, additional, Moscote-Salazar, Luis Rafael, additional, Lee, Ángel, additional, Jawad, Muhammad Youshay, additional, Ceban, Felicia, additional, Teopiz, Kayla M., additional, Mansur, Rodrigo B., additional, Ho, Roger, additional, Rosenblat, Joshua D., additional, Cao, Bing, additional, Rhee, Taeho Greg, additional, and McIntyre, Roger S., additional

Published
2023
Full Text
View/download PDF

103. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data

Author

d'Andrea, Giacomo, primary, Pettorruso, Mauro, additional, Di Lorenzo, Giorgio, additional, Rhee, Taeho Greg, additional, Chiappini, Stefania, additional, Carullo, Rosalba, additional, Barlati, Stefano, additional, Zanardi, Raffaella, additional, Rosso, Gianluca, additional, Di Nicola, Marco, additional, Andriola, Ileana, additional, Marcatili, Matteo, additional, Clerici, Massimo, additional, Dell'Osso, Bernardo Maria, additional, Sensi, Stefano L., additional, Mansur, Rodrigo B., additional, Rosenblat, Joshua D., additional, Martinotti, Giovanni, additional, and McIntyre, Roger S., additional

Published
2023
Full Text
View/download PDF

104. Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial

Author

McIntyre, Roger S, primary, Phan, Lee, additional, Kwan, Angela T H, additional, Mansur, Rodrigo B, additional, Rosenblat, Joshua D, additional, Guo, Ziji, additional, Le, Gia Han, additional, Lui, Leanna M W, additional, Teopiz, Kayla M, additional, Ceban, Felicia, additional, Lee, Yena, additional, Bailey, Julia, additional, Ramachandra, Ranuk, additional, Di Vincenzo, Joshua, additional, Badulescu, Sebastian, additional, Gill, Hartej, additional, Drzadzewski, Pawel, additional, and Subramaniapillai, Mehala, additional

Published
2023
Full Text
View/download PDF

105. Corrigendum to “Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in major depressive disorder” [J. Affect. Disord.. 238, 2018, pages 228–232]

Author

Cha, Danielle S., primary, Carmona, Nicole E., additional, Rodrigues, Nelson B., additional, Mansur, Rodrigo B., additional, Lee, Yena, additional, Subramaniapillai, Mehala, additional, Phan, Lee, additional, Cha, Rebekah H., additional, Pan, Zihang, additional, Lee, Jae Hon, additional, Lee, JungGoo, additional, Almatham, Fahad, additional, Alageel, Asem, additional, Rosenblat, Joshua D., additional, Shekotikhina, Margarita, additional, Rong, Carola, additional, Harrison, John, additional, and McIntyre, Roger S., additional

Published
2023
Full Text
View/download PDF

106. Real-World Effectiveness of Repeated Ketamine Infusions for Treatment-Resistant Bipolar Depression

Author

Fancy, Farhan, primary, Rodrigues, Nelson B., additional, Di Vincenzo, Joshua D., additional, Chau, Edmond H., additional, Sethi, Rickinder, additional, Husain, Muhammad I., additional, Gill, Hartej, additional, Tabassum, Aniqa, additional, Mckenzie, Andrea, additional, Phan, Lee, additional, McIntyre, Roger S., additional, and Rosenblat, Joshua D., additional

Published
2023
Full Text
View/download PDF

107. Contributors

Author

Ahearn, Eileen, primary, Al Mugaddam, Fadwa, additional, Amore, M., additional, Anastasia, A., additional, Andrews, Taylor, additional, Anmella, Gerard, additional, Arnone, Danilo, additional, Ashdown-Franks, Garcia, additional, Aziz, Karim Abdel, additional, Barichello, Tatiana, additional, Bauer, Moisés E., additional, Baune, Bernhard T., additional, Bellani, Marcella, additional, Bellivier, Frank, additional, Benedetti, Francesco, additional, Benevenuto, Deborah, additional, Bock, Nicholas A., additional, Bora, Emre, additional, Brambilla, Paolo, additional, Brunoni, Andre Russowsky, additional, Calabrese, Joseph R., additional, Camino, Sebastián, additional, Cararo, José H., additional, Carvalho, Andre Ferrer, additional, Ceylan, Deniz, additional, Chakrabarty, Trisha, additional, Chen, Peijun, additional, Cipriani, N., additional, Collodel, Allan, additional, Colombo, C., additional, Dallaspezia, Sara, additional, Del Fabro, Lorenzo, additional, DelBello, Melissa P., additional, Delvecchio, Giuseppe, additional, Doifode, Tejaswini, additional, DuBow, Anaïs, additional, Etain, Bruno, additional, Farrow, Jenni E., additional, Fernandes, Brisa S., additional, Fornaro, M., additional, Fregna, L., additional, Frey, Benicio N., additional, Fries, Gabriel R., additional, Fusco, A., additional, Gao, Keming, additional, Garza, Jacob C., additional, Gava, Fernanda F., additional, Generoso, Jaqueline S., additional, Giménez, Anna, additional, Giridharan, Vijayasree, additional, Goldstein, Benjamin I., additional, Gomes-da-Costa, Susana, additional, Grande, Iria, additional, Haggarty, Stephen J., additional, Hennion, Vincent, additional, Husain, Muhammad I., additional, Juster, Robert-Paul, additional, Kato, Tadafumi, additional, Keramatian, Kamyar, additional, Kloiber, Stefan, additional, Lima, Camila Nayane de Carvalho, additional, Locatelli, M., additional, Machado-Vieira, Rodrigo, additional, Melun, Jean-Pierre, additional, Meyer, Jeffrey H., additional, Mio, Megan, additional, Murru, Andrea, additional, Nery, Fabiano G., additional, Özerdem, Ayşegül, additional, Pacchiarotti, Isabella, additional, Pariante, Carmine Maria, additional, Patino, Luis Rodrigo, additional, Perlis, Roy H., additional, Pilieci, Christopher, additional, Pinjari, Omar F., additional, Pink, Omar, additional, Pinto, Jairo Vinícius, additional, Pisanu, Claudia, additional, Quevedo, Joao, additional, Rosenblat, Joshua D., additional, Sabiston, Catherine M., additional, Sajatovic, Martha, additional, Salagre, Estela, additional, de Sampaio Pereira Júnior, Bernardo, additional, Saraf, Gayatri, additional, Scaini, Giselli, additional, Seghi, F., additional, Sehmbi, Manpreet, additional, Serafini, G., additional, Sforzini, Luca, additional, Shahani, Lokesh, additional, Singhal, Gaurav, additional, Squassina, Alessio, additional, Stertz, Laura, additional, Teixeira, Antonio L., additional, Trinetti, Jessica, additional, Valvassori, Samira S., additional, Vázquez, Gustavo, additional, Vieta, Eduard, additional, Walss-Bass, Consuelo, additional, Wieck, Andrea, additional, Yatham, Lakshmi N., additional, and Zhao, Wen-Ning, additional

Published
2021
Full Text
View/download PDF

117. Applications of machine learning algorithms to predict therapeutic outcomes in depression: A meta-analysis and systematic review

Author

Lee, Yena, Ragguett, Renee-Marie, Mansur, Rodrigo B., Boutilier, Justin J., Rosenblat, Joshua D., Trevizol, Alisson, Brietzke, Elisa, Lin, Kangguang, Pan, Zihang, Subramaniapillai, Mehala, Chan, Timothy C.Y., Fus, Dominika, Park, Caroline, Musial, Natalie, Zuckerman, Hannah, Chen, Vincent Chin-Hung, Ho, Roger, Rong, Carola, and McIntyre, Roger S.

Published
2018
Full Text
View/download PDF

120. Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive Disorder

Author

Cha, Danielle S., Carmona, Nicole E., Rodrigues, Nelson B., Mansur, Rodrigo B., Lee, Yena, Subramaniapillai, Mehala, Phan, Lee, Cha, Rebekah H., Pan, Zihang, Lee, Jae Hon, Lee, JungGoo, Almatham, Fahad, Alageel, Asem, Rosenblat, Joshua D., Shekotikhina, Margarita, Rong, Carola, Harrison, John, and McIntyre, Roger S.

Published
2018
Full Text
View/download PDF

121. Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial.

Author

McIntyre, Roger S, Phan, Lee, Kwan, Angela T H, Mansur, Rodrigo B, Rosenblat, Joshua D, Guo, Ziji, Le, Gia Han, Lui, Leanna M W, Teopiz, Kayla M, Ceban, Felicia, Lee, Yena, Bailey, Julia, Ramachandra, Ranuk, Vincenzo, Joshua Di, Badulescu, Sebastian, Gill, Hartej, Drzadzewski, Pawel, and Subramaniapillai, Mehala

Subjects
RANDOMIZED controlled trials, QUALITY of life, COVID-19 pandemic, POST-acute COVID-19 syndrome, MENTAL depression
Abstract

Hitherto no therapeutic has received regulatory approval for the treatment of post-COVID-19 condition (PCC). Cognitive deficits, mood symptoms and significant reduction in health-related quality of life (HRQoL) are highly replicated and debilitating aspects of PCC. We sought to determine the impact of vortioxetine on the foregoing symptoms and HRQoL in persons living with PCC. An 8-week randomized, double-blind, placebo-controlled study of adults ≥ 18 years of age residing in Canada and who are experiencing symptoms of World Health Organization (WHO)-defined PCC, with a history of confirmed SARS-CoV-2 infection, was conducted. Recruitment began November 2021 and ended January 2023. Of the 200 participants enrolled (487 invited: 121 ineligible and 59 eligible but declined participation; 307 cleared pre-screening stage), a total of 149 participants were randomized (1:1) to receive either vortioxetine (5–20 mg, n = 75) or placebo (n = 74) daily for 8 weeks of double-blind treatment (i.e. end point). The primary outcome was the change from baseline-to-end point in the Digit Symbol Substitution Test. Secondary outcomes included the effect on depressive symptoms and HRQoL, as measured by changes from baseline-to-end point on the Quick Inventory of Depressive Symptomatology 16-item and WHO Wellbeing Scale 5-item, respectively. A total of 68 (90.7%) participants randomized to vortioxetine and 73 (98.6%) participants randomized to placebo completed all 8 weeks. Between-group analysis did not show a significant difference in the overall change in cognitive function [ P = 0.361, 95% confidence interval (CI) (−0.179, 0.492)]. However, in the fully adjusted model, a significant treatment × time interaction was observed in favour of vortioxetine treatment with baseline c-reactive protein (CRP) as a moderator (P = 0.012). In addition, a significant improvement in Digit Symbol Substitution Test scores were observed in vortioxetine versus placebo treated participants in those whose baseline CRP was above the mean (P = 0.045). Moreover, significant improvement was obtained in measures of depressive symptoms [ P < 0.001, 95% CI (−4.378, −2.323)] and HRQoL [ P < 0.001, 95% CI (2.297, 4.647)] in vortioxetine-treated participants and between the treatment groups [depressive symptoms: P = 0.026, 95% CI (−2.847, −0.185); HRQoL: P = 0.004, 95% CI (0.774, 3.938)]. Although vortioxetine did not improve cognitive function in the unadjusted model, when adjusting for CRP, a significant pro-cognitive effect was observed; antidepressant effects and improvement in HRQoL in this debilitating disorder were also noted. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

122. Psychotropic Drug–Related Weight Gain and Its Treatment.

Author

McIntyre, Roger S., Kwan, Angela T.H., Rosenblat, Joshua D., Teopiz, Kayla M., and Mansur, Rodrigo B.

Subjects
WEIGHT gain, DRUG side effects, PSYCHIATRIC drugs, DRUG therapy, BEHAVIOR modification
Abstract

Psychotropic drug–related weight gain (PDWG) is a common occurrence and is highly associated with non-initiation, discontinuation, and dissatisfaction with psychiatric drugs. Moreover, PDWG intersects with the elevated risk for obesity and associated morbidity that has been amply reported in the psychiatric population. Evidence indicates that differential liability for PDWG exists for antipsychotics, antidepressants, and anticonvulsants. During the past two decades, agents within these classes have become available with significantly lower or no liability for PDWG and as such should be prioritized. Although lithium is associated with weight gain, the overall extent of weight gain is significantly lower than previously estimated. The benefit of lifestyle and behavioral modification for obesity and/or PDWG in psychiatric populations is established, with effectiveness similar to that in the general population. Metformin is the most studied pharmacological treatment in the prevention and treatment of PDWG, and promising data are emerging for glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide, exenatide, semaglutide). Most pharmacologic antidotes for PDWG are supported with low-confidence data (e.g., topiramate, histamine-2 receptor antagonists). Future vistas for pharmacologic treatment for PDWG include large, adequately controlled studies with GLP-1 receptor agonists and possibly GLP-1/glucose-dependent insulinotropic polypeptide co-agonists (e.g., tirzepatide) as well as specific dietary modifications. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

123. Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions

Author

McIntyre, Roger S., primary, Alsuwaidan, Mohammad, additional, Baune, Bernhard T., additional, Berk, Michael, additional, Demyttenaere, Koen, additional, Goldberg, Joseph F., additional, Gorwood, Philip, additional, Ho, Roger, additional, Kasper, Siegfried, additional, Kennedy, Sidney H., additional, Ly‐Uson, Josefina, additional, Mansur, Rodrigo B., additional, McAllister‐Williams, R. Hamish, additional, Murrough, James W., additional, Nemeroff, Charles B., additional, Nierenberg, Andrew A., additional, Rosenblat, Joshua D., additional, Sanacora, Gerard, additional, Schatzberg, Alan F., additional, Shelton, Richard, additional, Stahl, Stephen M., additional, Trivedi, Madhukar H., additional, Vieta, Eduard, additional, Vinberg, Maj, additional, Williams, Nolan, additional, Young, Allan H., additional, and Maj, Mario, additional

Published
2023
Full Text
View/download PDF

125. List of Contributors

Author

Ali, Fariya, primary, Bani-Fatemi, Ali, additional, Bauer, Isabelle E., additional, Baune, Bernhard T., additional, Bhat, Venkat, additional, Chee, Justin N., additional, Cheung, Amy, additional, Coles, Alexandria S., additional, Cooper, Timothy M., additional, Dada, Oluwagbenga O., additional, De Luca, Vincenzo, additional, Dunn, Erin C., additional, Giacobbe, Peter, additional, Graff, Ariel, additional, Greer, Tracy L., additional, Iosifescu, Dan V., additional, Joseph, Jeethu K., additional, Kim, Jungjin, additional, Lee, Yena, additional, Man Ho, Roger Chun, additional, McIntyre, Roger S., additional, Melicher, Tomas, additional, Meng, Ying, additional, Mithani, Karim, additional, Monda, Marcellino, additional, Nemeroff, Charles B., additional, Perlis, Roy H., additional, Rajagopalan, Arvind, additional, Rosenblat, Joshua D., additional, Sanches, Marsal, additional, Schwartz, Thomas L., additional, Singhal, Gaurav, additional, Soares, Jair C., additional, Subramaniapillai, Mehala, additional, Tasmim, Samia, additional, Wang, Karen, additional, Wang, Kevin Z., additional, Wang, Min-Jung, additional, and Wu, Hanjing, additional

Published
2020
Full Text
View/download PDF

131. Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth

Author

Chisamore, Noah, primary, Danayan, Kevork, additional, Rodrigues, Nelson B, additional, Di Vincenzo, Joshua D, additional, Meshkat, Shakila, additional, Doyle, Zoe, additional, Mansur, Rodrigo, additional, Phan, Lee, additional, Fancy, Farhan, additional, Chau, Edmond, additional, Tabassum, Aniqa, additional, Kratiuk, Kevin, additional, Arekapudi, Anil, additional, McIntyre, Roger S, additional, and Rosenblat, Joshua D., additional

Published
2023
Full Text
View/download PDF

133. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)

Author

McIntyre, Roger S., Mansur, Rodrigo B., Rosenblat, Joshua D., and Kwan, Angela T.H.

Abstract

ABSTRACTIntroductionRecently, the European Medicines Agency (EMA) received reports of suicidal thoughts and self-injury associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) liraglutide and semaglutide.Research design and methodsHerein, we sought to evaluate suicidality associated with all GLP-1 RAs relative to other glucose-lowering agents currently approved by the United States Food and Drug Administration (FDA). Reports of suicidal ideation, “depression/suicidal”, suicidal behavior, suicidal attempts, and completed suicide associated with GLP-1 RA exposure reported to the FDA between 2005 and October 2023 were obtained from the FDA Adverse Event Reporting System (FAERS). We present data using the reporting odds ratio (ROR). The ROR was considered significant when the lower limit of the 95% confidence interval (CI) was greater than 1.0.ResultsDisproportionate reporting of suicidal ideation and “depression/suicidal” was observed with semaglutide and liraglutide. Disproportionate reporting of suicidal behavior, suicide attempts, and completed suicide was not observed for any of the FDA-approved GLP-1 RAs.ConclusionsUsing the Bradford Hill criteria, however, and taking into consideration confounders, no causal link between GLP-1 RAs and suicidality exists.

Published
2024
Full Text
View/download PDF

134. Pain and major depressive disorder: Associations with cognitive impairment as measured by the THINC-integrated tool (THINC-it)

Author

Cha, Danielle S., Carmona, Nicole E., Mansur, Rodrigo B., Lee, Yena, Park, Hyun Jung, Rodrigues, Nelson B., Subramaniapillai, Mehala, Rosenblat, Joshua D., Pan, Zihang, Lee, Jae Hon, Lee, JungGoo, Almatham, Fahad, Alageel, Asem, Shekotikhina, Margarita, Zhou, Aileen J., Rong, Carola, Harrison, John, and McIntyre, Roger S.

Published
2017
Full Text
View/download PDF

141. Association of SARS-CoV-2 Infection with Neurological Symptoms and Neuroimaging Manifestations in the Pediatric Population: A Systematic Review

Author

Kwan, Angela T.H., primary, Al-Kassimi, Khaled, additional, Portnoff, Jacob S., additional, Tesla, Marija, additional, Hanafimosalman, Mehrshad, additional, Gharibi, Nima, additional, Ni, Tiffany, additional, Sonfack, Davaine J.N., additional, Martyniuk, Julia, additional, Arfaie, Saman, additional, Mashayekhi, Mohammad Sadegh, additional, Mofatteh, Mohammad, additional, Jeremian, Richie, additional, Moscote-Salazar, Luis Rafael, additional, Lee, Ángel, additional, Jawad, Muhammad Youshay, additional, Guo, Ziji, additional, Ceban, Felicia, additional, Teopiz, Kayla M., additional, Mansur, Rodrigo B., additional, Ho, Roger, additional, Rosenblat, Joshua D., additional, Cao, Bing, additional, Rhee, Taeho Greg, additional, and McIntyre, Roger S., additional

Published
2023
Full Text
View/download PDF

144. Biomarkers of ketamine's antidepressant effect: An umbrella review

Author

Meshkat, Shakila, primary, Ho, Roger C., additional, Cao, Bing, additional, Teopiz, Kayla M., additional, Rosenblat, Joshua D., additional, Rhee, Taeho Greg, additional, Di Vincenzo, Joshua D., additional, Ceban, Felicia, additional, Jawad, Muhammad Youshay, additional, and McIntyre, Roger S., additional

Published
2023
Full Text
View/download PDF

146. Oral ketamine for depression: An updated systematic review

Author

Meshkat, Shakila, primary, Haikazian, Sipan, additional, Di Vincenzo, Joshua D., additional, Fancy, Farhan, additional, Johnson, Danica, additional, Chen-Li, David, additional, McIntyre, Roger S., additional, Mansur, Rodrigo, additional, and Rosenblat, Joshua D., additional

Published
2023
Full Text
View/download PDF

147. A Phase II, Open-Label Clinical Trial of Intranasal Ketamine for Depression in Patients with Cancer Receiving Palliative Care (INKeD-PC Study)

Author

Rosenblat, Joshua D., primary, deVries, Froukje E., additional, Doyle, Zoe, additional, McIntyre, Roger S., additional, Rodin, Gary, additional, Zimmermann, Camilla, additional, Mak, Ernie, additional, Hannon, Breffni, additional, Schulz-Quach, Christian, additional, Kindy, Aida Al, additional, Patel, Zeal, additional, and Li, Madeline, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results